Welcome to Elusys Therapeutics, Inc. Elusys is a private, commercial-stage biopharmaceutical company that has achieved US and international licensure in Canada, the UK, and the EU for its lead antibody therapeutic, a medical countermeasure to treat patients following anthrax exposure after a natural or intentional terrorist incident. OUR PRODUCTS Learn more OUR PARTNERS About Us PRESS RELEASES December 2, 2020 Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax Read more October 8, 2020 Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax Read more August 12, 2020 Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax Read more April 23, 2018 Elusys receives second delivery order from U.S. government for Anthim®, its treatment for Inhalation Anthrax Read more October 10, 2017 Elusys delivers first shipment of ANTHIM®, its treatment for Inhalational Anthrax, to U.S. Government Strategic National Stockpile Read more January 24, 2017 Elusys Receives $16.35 Million for Delivery of ANTHIM® to U.S. Government Read more View All Press Releases PUBLICATIONS Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre-and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax View Publications About Us What We Do Our Products Leadership Executive Team Board of Directors Our Partners About Anthrax What is anthrax? The threat of anthrax Transmission and spread of anthrax Symptoms of inhalation anthrax Anthrax Treatment Media Center Press Releases Resources and Links Publications Contact Us Site Map Privacy Terms And Conditions Copyright 2021 Elusys Therapeutics, Inc. All Rights Reserved.